Relevant bibliographies by topics / Paraneoplastic neurological syndromes / Journal articles
To see the other types of publications on this topic, follow the link: Paraneoplastic neurological syndromes.

Journal articles on the topic 'Paraneoplastic neurological syndromes'

Author: Grafiati
Published: 21 December 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Paraneoplastic neurological syndromes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pathirana, KD. "Paraneoplastic neurological syndromes." Ceylon Medical Journal 53, no. 4 (January 26, 2009): 148. http://dx.doi.org/10.4038/cmj.v53i4.290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chad, David A., and Lawrence D. Recht. "Neurological Paraneoplastic Syndromes." Cancer Investigation 6, no. 1 (January 1988): 67–82. http://dx.doi.org/10.3109/07357908809077030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bashir, R., and F. Hochberg. "Paraneoplastic Neurological Syndromes." Cancer Investigation 6, no. 1 (January 1988): 117–18. http://dx.doi.org/10.3109/07357908809077035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nath, U., and R. Grant. "Neurological paraneoplastic syndromes." Journal of Clinical Pathology 50, no. 12 (December 1, 1997): 975–80. http://dx.doi.org/10.1136/jcp.50.12.975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sutton, Ian. "Paraneoplastic neurological syndromes." Current Opinion in Neurology 15, no. 6 (December 2002): 685–90. http://dx.doi.org/10.1097/00019052-200212000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sutton, Ian. "Paraneoplastic neurological syndromes." Current Opinion in Neurology 15, no. 6 (December 2002): 685–90. http://dx.doi.org/10.1097/01.wco.0000044764.39452.64.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Leypoldt, F., and K. P. Wandinger. "Paraneoplastic neurological syndromes." Clinical & Experimental Immunology 175, no. 3 (February 4, 2014): 336–48. http://dx.doi.org/10.1111/cei.12185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dalmau, Josep O., and Jerome B. Posner. "Neurological Paraneoplastic Syndromes." Neuroscientist 4, no. 6 (November 1998): 443–53. http://dx.doi.org/10.1177/107385849800400616.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smitt, Peter Sillevis. "Paraneoplastic neurological syndromes." Lancet Neurology 1, no. 7 (November 2002): 408. http://dx.doi.org/10.1016/s1474-4422(02)00218-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Graus, Francesc, and Josep Dalmau. "Paraneoplastic neurological syndromes." Current Opinion in Neurology 25, no. 6 (December 2012): 795–801. http://dx.doi.org/10.1097/wco.0b013e328359da15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Toothaker, Thomas B., and Michael Rubin. "Paraneoplastic Neurological Syndromes." Neurologist 15, no. 1 (January 2009): 21–33. http://dx.doi.org/10.1097/nrl.0b013e3181870aa2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Iorio, Raffaele, Gregorio Spagni, and Gianvito Masi. "Paraneoplastic neurological syndromes." Seminars in Diagnostic Pathology 36, no. 4 (July 2019): 279–92. http://dx.doi.org/10.1053/j.semdp.2019.06.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Dalmau, Josep, and Jerome B. Posner. "Neurological paraneoplastic syndromes." Springer Seminars in Immunopathology 18, no. 1 (1996): 85–95. http://dx.doi.org/10.1007/bf00792611.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Fathallah-Shaykh, Hassan M. "Paraneoplastic Neurological Syndromes." Archives of Neurology 56, no. 2 (February 1, 1999): 151. http://dx.doi.org/10.1001/archneur.56.2.151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Devine, Michelle F., Naga Kothapalli, Mahmoud Elkhooly, and Divyanshu Dubey. "Paraneoplastic neurological syndromes: clinical presentations and management." Therapeutic Advances in Neurological Disorders 14 (January 2021): 175628642098532. http://dx.doi.org/10.1177/1756286420985323.

Full text
Abstract:
We provide an overview of the varied presentations of paraneoplastic neurological syndromes. We also review the onconeural antibodies and their particular oncological and neurological associations. Recognition of these syndromes and their oncological associations is crucial, as early diagnosis and management has been associated with better patient outcomes. Specific management strategies and prognosis vary widely depending on the underlying etiology. An understanding of the relevant clinical details, imaging findings, and other diagnostic information can help tailor treatment approaches. We provide an outline of the diagnostic evaluation and treatment of various paraneoplastic neurological disorders, presenting with central and/or peripheral nervous system involvement. We briefly discuss neurologic immune checkpoint inhibitor-related adverse events, which can occasionally present with paraneoplastic neurological syndrome phenotypes.
APA, Harvard, Vancouver, ISO, and other styles
16

Erraichi, Hayat, Niaina Ezra Randriamanovontsoa, Valère Litique, Jean-Marc Limacher, S. Berrad, Karima Oualla, Lamiae Ammadour, Zineb Benbrahim, S. Arifi, and Nawfal Mellas. "Ovarian Cancer Revealed by Paraneoplastic Cerebellar Degeneration Anti-Yo Positive: A Case Report." International Journal of Innovative Research in Medical Science 5, no. 12 (December 20, 2020): 635–37. http://dx.doi.org/10.23958/ijirms/vol05-i12/1016.

Full text
Abstract:
Neurological paraneoplastic syndromes are rare, often associated with gynecological cancer or small cell lung cancer. This article reports a case of ovarian cancer to discuss the difficulties in the management of neurological paraneoplastic syndromes. This is a case of paraneoplastic cerebellar syndrome with anti-Yo antibodies. Neurological syndromes, testing for onconeural antibodies and testing for underlying cancer provide a basis for the diagnosis. The anti-tumor treatment constitutes the mainstay of the care.
APA, Harvard, Vancouver, ISO, and other styles
17

Pranzatelli, M. R. "Peripheral neurological paraneoplastic syndromes." Drugs of Today 34, no. 7 (1998): 625. http://dx.doi.org/10.1358/dot.1998.34.7.485261.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Lorusso, Lorenzo, Ian K. Hart, Daniela Ferrari, Gaelle K. Ngonga, Chiara Gasparetto, and Giovanni Ricevuti. "Autonomic paraneoplastic neurological syndromes." Autoimmunity Reviews 6, no. 3 (January 2007): 162–68. http://dx.doi.org/10.1016/j.autrev.2006.10.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Joy, Shiny, Ayush Agarwal, Shamim Ahmed Shamim, and Ajay Garg. "Seronegative paraneoplastic encephalomyelitis in occult colonic carcinoma." BMJ Case Reports 16, no. 9 (September 2023): e254397. http://dx.doi.org/10.1136/bcr-2022-254397.

Full text
Abstract:
Paraneoplastic neurological syndromes are immune-mediated neurological attacks triggered by malignancies. They are commonly associated with lung, breast, thymus, gynaecological and haematological malignancies. We report a case of a male patient in his late 40s with paraneoplastic encephalomyelitis due to a colonic adenocarcinoma emphasising a low threshold for extensive cancer evaluation in all subacutely presenting neurological syndromes. We also emphasise that the absence of a positive onconeural antibody does not preclude the diagnosis of a paraneoplastic syndrome.
APA, Harvard, Vancouver, ISO, and other styles
20

Yang, Ingrid, Joanna Jaros, and Danny Bega. "Paraneoplastic Peripheral Nervous System Manifestations of Renal Cell Carcinoma: A Case Report and Review of the Literature." Case Reports in Neurology 9, no. 1 (February 20, 2017): 22–30. http://dx.doi.org/10.1159/000458435.

Full text
Abstract:
Neurologic symptoms secondary to a paraneoplastic syndrome may be the presenting manifestation of a previously undiagnosed cancer, and alertness to these syndromes may provide an opportunity for early detection and treatment of a cancer. Paraneoplastic weakness is a rare manifestation of renal cell carcinoma and may present with variable electrophysiological features. We present a case of a patient with progressive weakness, sensory changes, and urinary retention, with electrophysiological features suggestive of a complex peripheral nervous system syndrome. Ultimately, a renal cell mass was detected and resected, resulting in significant clinical improvement. We review the literature, cataloging the known neurologic syndromes and antibodies associated with renal cell carcinoma. This case highlights that paraneoplastic neurological disorders associated with RCC can take on many features and provides a resource to practitioners for early detection of a neurologic paraneoplastic syndrome arising from renal cell carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
21

Avino, Gianluca, Fabiola De Marchi, Roberto Cantello, and Letizia Mazzini. "Anti-Yo Paraneoplastic Cerebellar Degeneration and Breast Cancer: A Long Survival of Persistent Cerebellar Syndrome." Sclerosis 1, no. 1 (November 29, 2022): 5–8. http://dx.doi.org/10.3390/sclerosis1010002.

Full text
Abstract:
Paraneoplastic neurological syndromes (PNS) occur in 1–3% of all cancer patients with several cancer-related neurologic diseases involving any part of the nervous system. Paraneoplastic cerebellar degeneration (PCD) is a specific type of PNS characterized by sub-acute cerebellar syndrome with trunk and limb ataxia, dysarthria, diplopia, and vertigo. We report herein the case of a 70-year-old female patient with cerebellar symptoms and transient anti-Yo antibody PCD positivity manifested three years after a breast cancer diagnosis who is currently neurologically stable after an extended follow-up.
APA, Harvard, Vancouver, ISO, and other styles
22

Höftberger, Romana, Myrna R. Rosenfeld, and Josep Dalmau. "Update on neurological paraneoplastic syndromes." Current Opinion in Oncology 27, no. 6 (November 2015): 489–95. http://dx.doi.org/10.1097/cco.0000000000000222.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Didelot, Adrien, and Jérôme Honnorat. "Update on paraneoplastic neurological syndromes." Current Opinion in Oncology 21, no. 6 (November 2009): 566–72. http://dx.doi.org/10.1097/cco.0b013e3283306647.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Honnorat, Jérôme, and Stéphanie Cartalat-Carel. "Advances in paraneoplastic neurological syndromes." Current Opinion in Oncology 16, no. 6 (November 2004): 614–20. http://dx.doi.org/10.1097/01.cco.0000142486.89472.eb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Voltz, Raymond. "Paraneoplastic neurological syndromes – Author's reply." Lancet Neurology 1, no. 7 (November 2002): 408. http://dx.doi.org/10.1016/s1474-4422(02)00219-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Vedeler, C. "240 INVITED Paraneoplastic Neurological Syndromes." European Journal of Cancer 47 (September 2011): S57. http://dx.doi.org/10.1016/s0959-8049(11)70455-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Giannopoulou, Chariklia. "Navigating the paraneoplastic neurological syndromes." European Journal of Nuclear Medicine and Molecular Imaging 30, no. 3 (March 2003): 333–38. http://dx.doi.org/10.1007/s00259-002-1005-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Giometto, B., B. Taraloto, and F. Graus. "Autoimmunity in Paraneoplastic Neurological Syndromes." Brain Pathology 9, no. 2 (April 5, 2006): 261–73. http://dx.doi.org/10.1111/j.1750-3639.1999.tb00225.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Zoccarato, Marco, Matteo Gastaldi, Luigi Zuliani, Tiziana Biagioli, Marco Brogi, Gaetano Bernardi, Elena Corsini, et al. "Diagnostics of paraneoplastic neurological syndromes." Neurological Sciences 38, S2 (October 2017): 237–42. http://dx.doi.org/10.1007/s10072-017-3031-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Kamimura, Hiroteru, Tomohiro Iwasaki, Kazunao Hayashi, and Shuji Terai. "Rare paraneoplastic syndromes in digestive systems caused by lung cancer." BMJ Case Reports 14, no. 2 (February 2021): e240161. http://dx.doi.org/10.1136/bcr-2020-240161.

Full text
Abstract:
We observed a rare case of two different digestive paraneoplastic syndromes that improved with the treatment of the neoplasms. The first syndrome was chronic intestinal pseudo-obstruction (CIPO), which is a subtype of paraneoplastic syndromes called a paraneoplastic neurological syndrome (PNS). The second was Stauffer’s syndrome, which is a unique paraneoplastic syndrome characterised by non-metastatic intrahepatic cholestasis associated with neoplasms. Here, we report the case of a 55-year-old man who presented with two concurrent paraneoplastic syndromes in the digestive system. The intestinal pseudo-obstruction and elevated biliary enzyme levels improved as the lung cancer responded to chemotherapy. In this case, CIPO as a PNS led to the detection of lung cancer. To our knowledge, this is the first report of Stauffer’s syndrome caused by lung adenocarcinoma.
APA, Harvard, Vancouver, ISO, and other styles
31

Chakravarthy, Krishnan. "Updated Review and Treatment Recommendations on Paraneoplastic Neurologic Syndromes and Chronic Pain." Pain Physician 5, no. 22;5 (September 11, 2019): 433–45. http://dx.doi.org/10.36076/ppj/2019.22.433.

Full text
Abstract:
Background: This comprehensive review of pain in paraneoplastic neurological syndromes focuses on current mechanisms that lead to pain, including autoimmune processes as well as the systemic secretion of factors that sensitize nociceptive nerves. Systemic secretion of functional molecules is a well-recognized phenomenon in endocrine paraneoplastic syndromes; however, cancer pain research has predominantly focused on cytokine-nerve interactions in the tumor microenvironment, and few groups have applied the molecular mechanisms of local pain to study widespread neuropathic pain resulting from systemic secretion. We present a novel perspective in the field of pain research by converging data from clinical oncology with recent molecular pain research on cytokine-mediated sensitization of nociceptive nerves. Objective: Our objective was to conduct a review of paraneoplastic neurological syndromes and provide updates on therapeutic recommendations. Study Design: We used a narrative review design. Methods: This review was done using searches of PubMed, MEDLINE/OVID, SCOPUS, and manual searches of the bibliographies of known primary and review articles from inception to the present date. Other data sources included hand searches of publications driven by manuscript authors. Search terms included concepts of paraneoplastic syndrome and chronic pain with emphasis on both preclinical and clinical studies. Results: Articles were screened by title, abstract, and full article review. They were then analyzed by specific clinical indications and appropriate data was presented based on critical analysis of those articles. Limitations: More studies that distinguish autoimmune paraneoplastic pain syndromes from those related to systemic cytokine secretion are required. Conclusion: By providing a unified review across disciplines, we illustrate that neuropathic pain related to the systemic secretion of cytokines may represent another category of paraneoplastic neurological syndromes distinct from the well-known autoimmune neuronopathies. In addition, we discuss the clinical significance of distinguishing autoimmune paraneoplastic pain syndromes from those related to systemic cytokine secretion and highlight the need for further research at the intersection of these fields. This review takes a look at both past and current literature with a critical analysis of findings and respective recommendations. In addition, based on review of the literature we provide updated therapeutic recommendations for the consideration of pain practitioners when dealing with this patient population. Keywords: Paraneoplastic neurologic syndromes, chronic pain, neuropathic pain, treatment guidelines, cytokines
APA, Harvard, Vancouver, ISO, and other styles
32

Rudnicka, Halina, Agnieszka I. Jagiello Gruszfeld, and Iwona Glogowska. "Antigens diagnoses in paraneoplastic neurological syndromes." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10582. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10582.

Full text
Abstract:
10582 Background: At present, paraneoplasmatic neurological syndroms (PNS) are thought to be autoimmunological disorders. Neurological symptoms in PNS result from the disturbance of the nervous system, with a participation of the immune response triggered by the aberrant expression of the so-called onconeuronal antigens of a tumour. Very important for PNS diagnostics is the investigation of antineuronal antibodies (ANA) in the serum. Different types of ANA are frequently associated with specific tumors and with specific neurological syndromes.Investigations of serum ANA in patients with breast cancer with the symptoms of PNS. Methods: Investigations of ANA in serum were performed with the indirect immunofluorescence test but the type of ANA was analyzed by the Western Blot (WB) method . The presence of these antibodies which are included to the group of “the so called well characterized” is believed to be a definite (95 – 100%) determinant of the PNS diagnosis. Results: We examined 147 patients with breast cancer suspected to have PNS, hospitalized at Breast Cancer Clinic of the Institute of Oncology in Warsaw. The immunofluorescence test was positive in 92 patients, however in 24 patients the WB occurrence of “the well characterized” antibodies was found. In this group we observed: in 4 patients the cerebellar degeneration (anti-Yo, anti-Ma2); in 6 patients brainstem encephalitis and encephalomyelitis combined with sensory neuropathy (anti-Ma2, anti-CV2, anti-Yo, anti-Hu, anti-Ri); 4 myastenic syndrome (anti-Hu,anti-Ri,anti-Ma2/Ta); 5 sensory neuropathy (anti-Hu, anti-Yo, anti-Ma2, anti-Ri); and in single cases we also observed polyneuropathy: Guillain-Barre (Ma2): Miller-Fisher syndrom (anti-Ma2/Ta); cancer-associated retinopathy (anti-Yo); dermatomyositis (anti-Ri) and scleroderma (anti-Yo). Conclusions: Our analysis indicates that the investigation of the presence of ANA in the serum is the important in the diagnosis of PNS in patients with breast cancer. The types of ANA correspond to the individual paraneoplastic neurological syndromes which opens the proper methods of treatment in PNS.
APA, Harvard, Vancouver, ISO, and other styles
33

Opalińska, Marta, Anna Sowa-Staszczak, Kamil Wężyk, Jeremiasz Jagiełła, Agnieszka Słowik, and Alicja Hubalewska-Dydejczyk. "Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging." Journal of Clinical Medicine 11, no. 6 (March 11, 2022): 1537. http://dx.doi.org/10.3390/jcm11061537.

Full text
Abstract:
Background: Paraneoplastic neurological syndromes (PNS) affecting the CNS (central nervous system) are rare, presenting in less than 1% of all those with cancer. The pathogenesis of paraneoplastic neurological syndromes is not fully understood, but it is presumed to result from an immune attack on the underlying malignancy. The presence of different types of onconeural antibodies may occur in different tumors and can lead to different clinical manifestations, making the early detection of cancers challenging. Aim: An evaluation of [18F]FDG PET/CT in neoplastic tumor detection in patients with paraneoplastic neurological syndromes having negative or unremarkable results of conventional radiological imaging. Methods: Among all patients diagnosed with paraneoplastic neurological syndromes in the Neurology Department in 2016–2020, 15 patients with unremarkable conventional radiological findings who underwent [18F]FDG PET/CT were included in the study. Results: [18F]FDG PET/CT enabled localization of suspected malignancy in 53% (8 of 15) of PNS cases with previous unremarkable conventional radiological findings. Conclusion: [18F]FDG PET/CT may be considered as a useful tool for neoplastic tumor detection in patients with paraneoplastic neurological syndromes, accelerating the diagnostic process and enabling faster initiation of appropriate treatment.
APA, Harvard, Vancouver, ISO, and other styles
34

Rajan, Archana, and Abhisek Sahoo. "Paraneoplastic Syndromes in Small Cell Lung Cancer: A Narrative Review." International Journal of Research and Review 10, no. 7 (July 19, 2023): 660–70. http://dx.doi.org/10.52403/ijrr.20230778.

Full text
Abstract:
Paraneoplastic syndromes are commonly associated with lung cancer, particularly small-cell lung cancer. These syndromes often occur before the cancer is diagnosed or in the early stages of the disease. However, they can also occur at the time of metastasis. Through this article, we want to focus on the epidemiology, pathophysiology, symptoms, and current treatment approaches for the most frequent paraneoplastic syndromes seen in patients with small-cell lung cancer. Recent advancements have improved our understanding of these syndromes and provided better diagnostic and therapeutic options. Being aware of paraneoplastic syndromes in small-cell lung cancer can lead to earlier detection and diagnosis, potentially improving the overall prognosis and survival rates for patients. Further studies are needed to investigate effective strategies in patients with paraneoplastic neurological disorders. Keywords: Paraneoplastic syndrome, small cell lung cancer, hypercalcemia
APA, Harvard, Vancouver, ISO, and other styles
35

Grigoryeva, V. N., and E. A. Ruina. "Paraneoplastic neurological syndromes: upgraded approaches to diagnosis." Russian neurological journal 29, no. 1 (March 11, 2024): 4–13. http://dx.doi.org/10.30629/2658-7947-2024-29-1-4-13.

Full text
Abstract:
Paraneoplastic neurological syndromes (PNNS) are neurological disorders due to autoimmune attack on the nervous system, induced by a tumor remote from these structures. The existence of relatively stable associations between the neurological syndrome, the type of antineuronal antibodies (Ab) and the nature of tumor has been proven. At the same time, there are no pathognomonic combinations of this kind: the same antibodies can be detected in diff erent types of tumors and in diff erent syndromes. In addition, level of reliability of the diagnosis of PNNS is considered, taking into account the phenotype of the neurological disorder, the presence of certain antibodies in the blood serum, the verifi cation of oncopathology and the duration of the observation for the patient.
APA, Harvard, Vancouver, ISO, and other styles
36

Dai, Yi-Ling, Ling Xiao, Zhen Pan, Guo-Qian He, Ju Gao, Xia Guo, and Zhuo Huang. "Anti-Hu antibody associated paraneoplastic neurological syndrome in a child with ganglioneuroblastoma: A rare case report and literature review." Medicine 103, no. 19 (May 10, 2024): e38148. http://dx.doi.org/10.1097/md.0000000000038148.

Full text
Abstract:
Rationale: Paraneoplastic neurological syndrome with anti-Hu antibody (Hu-PNS) is a neurological disorder that occur in patients with malignancy. The syndrome has a wide range of presentations and can present before diagnosis of primary malignancy. Familiarity with these paraneoplastic neurological syndromes can help early recognition and take appropriate regimens. Patients concerns: Diagnosis and treatment of Hu-PNS. Diagnoses: This is retrospective study that analyzed the clinical data of this case. Through retrospective analysis and targeted antibody screening, serum anti-Hu antibody was detected. Subsequent spinal imaging revealed a mass in the paraspinal region, which was confirmed as ganglioneuroblastoma by pathologic examination. Interventions: The child was treated with a course of intravenous immunoglobulin and radical surgical operation without chemotherapy. Outcomes: The neurological symptoms were gradually improved and no signs indicate disease progression or tumor recurrence. Lessons: Hu-PNS has rarely been reported in children with ganglioneuroblastomas. They can mimic non-neoplastic processes, making detection and diagnosis difficult. Serum and/or cerebrospinal fluid onconeural antibody can strongly indicate occult cancers. Early detection of paraneoplastic neurological syndromes can help take appropriate regimens and improve prognosis.
APA, Harvard, Vancouver, ISO, and other styles
37

Samaha, Shehab, and Andrew J. Larner. "Cerebellar syndrome: cause cured, but symptoms persist." Progress in Neurology and Psychiatry 27, no. 4 (October 2023): 27–29. http://dx.doi.org/10.1002/pnp.812.

Full text
Abstract:
Subacute cerebellar syndromes have a broad differential diagnosis, which includes paraneoplasia. Paraneoplastic cerebellar degeneration needs to be considered in this clinical situation even if initial brain imaging is normal, and the neurological prognosis is guarded even if the underlying tumour can be successfully treated.
APA, Harvard, Vancouver, ISO, and other styles
38

Deleva, Nadezhda. "Neurological paraneoplastic syndromes in education and neurological practice." Scripta Scientifica Medica 39, no. 2 (December 20, 2007): 155. http://dx.doi.org/10.14748/ssm.v39i2.489.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

SUTTON, Ian, and John B. WINER. "The immunopathogenesis of paraneoplastic neurological syndromes." Clinical Science 102, no. 5 (April 12, 2002): 475–86. http://dx.doi.org/10.1042/cs1020475.

Full text
Abstract:
Paraneoplastic neurological syndromes are rare non-metastatic complications of cancer that have an immune-mediated aetiology. The central and peripheral nervous systems are considered to be immune-privileged sites, since the presence of the ‘blood-brain/nerve barrier’ means that antigens sequestered within the nervous system do not normally induce an immune response. Aberrant expression of a neuronal antigen by a tumour arising outside this barrier can lead to the breakdown of immune tolerance to the nervous system. However, in many cases the immune mechanisms that result in neurological dysfunction remain poorly defined. Furthermore, aberrant expression of neuronal antigens can be detected in many tumours that are not complicated by non-metastatic neurological syndromes. This review article examines current concepts in the immunopathogenesis of paraneoplastic neurological syndromes.
APA, Harvard, Vancouver, ISO, and other styles
40

Tanaka, Keiko. "Diagnostic Significance of Paraneoplastic Neurological Syndromes." Nihon Naika Gakkai Zasshi 97, no. 8 (2008): 1761–63. http://dx.doi.org/10.2169/naika.97.1761.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Nomura, Kyoichi. "2. Immunotherapy for Paraneoplastic Neurological Syndromes." Nihon Naika Gakkai Zasshi 97, no. 8 (2008): 1830–37. http://dx.doi.org/10.2169/naika.97.1830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Hansra, Damien, and Stefan Glück. "Paraneoplastic neurological syndromes in breast cancer." Breast Cancer Management 3, no. 1 (January 2014): 113–20. http://dx.doi.org/10.2217/bmt.13.65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Symonds, R. P., R. B. Hogg, and I. Bone. "Paraneoplastic Neurological Syndromes Associated with Lymphomas." Leukemia & Lymphoma 15, no. 5-6 (January 1994): 487–90. http://dx.doi.org/10.3109/10428199409049752.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

SUTTON, Ian, and John B. WINER. "The immunopathogenesis of paraneoplastic neurological syndromes." Clinical Science 102, no. 5 (May 1, 2002): 475. http://dx.doi.org/10.1042/cs20010121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Lorusso, L., I. K. Hart, B. Giometto, R. Pezzani, J. C. Broome, D. Gritti, C. Gasparetto, and G. Ricevuti. "Immunological Features of Paraneoplastic Neurological Syndromes." International Journal of Immunopathology and Pharmacology 17, no. 2 (May 2004): 135–44. http://dx.doi.org/10.1177/039463200401700205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Graus, Francesc, and Josep Dalmau. "Paraneoplastic neurological syndromes: diagnosis and treatment." Current Opinion in Internal Medicine 7, no. 1 (February 2008): 82–87. http://dx.doi.org/10.1097/wco.0b013e3282f189dc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Honnorat, J., and A. Viaccoz. "New concepts in paraneoplastic neurological syndromes." Revue Neurologique 167, no. 10 (October 2011): 729–36. http://dx.doi.org/10.1016/j.neurol.2011.08.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Joubert, Bastien, and Jérôme Honnorat. "Autoimmune channelopathies in paraneoplastic neurological syndromes." Biochimica et Biophysica Acta (BBA) - Biomembranes 1848, no. 10 (October 2015): 2665–76. http://dx.doi.org/10.1016/j.bbamem.2015.04.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Blaes, Franz. "Paraneoplastic Neurological Syndromes - Diagnosis and Management." Current Pharmaceutical Design 18, no. 29 (August 15, 2012): 4518–25. http://dx.doi.org/10.2174/138161212802502323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Viaccoz, Aurélien, and Jérôme Honnorat. "Paraneoplastic Neurological Syndromes: General Treatment Overview." Current Treatment Options in Neurology 15, no. 2 (February 24, 2013): 150–68. http://dx.doi.org/10.1007/s11940-013-0220-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography